<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04226495</url>
  </required_header>
  <id_info>
    <org_study_id>123-20-FB</org_study_id>
    <nct_id>NCT04226495</nct_id>
  </id_info>
  <brief_title>Sufentanil Infusion vs Sufentanil Bolus</brief_title>
  <official_title>Sufentanil Infusion vs Sufentanil Bolus and Time to Extubation During Routine Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nebraska</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Nebraska</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized single blind controlled clinical trial to test the benefit of sufentanil infusion&#xD;
      over bolus dosing to reduce time to extubation and reduced length of ICU stay.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 13, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to extubation</measure>
    <time_frame>60 minutes</time_frame>
    <description>Sufentanil infusion administration intra-operatively during routine cardiac surgery decreases time to extubation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration</measure>
    <time_frame>intra-operative</time_frame>
    <description>Sufentanil infusion administration intra-operatively during routine cardiac surgery results in a lower plasma concentration of sufentanil at time of arrival to ICU.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Sufentanil Bolus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sufentanil Infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sufentanil Infusion</intervention_name>
    <description>Intra-operative sufentanil infusion</description>
    <arm_group_label>Sufentanil Infusion</arm_group_label>
    <other_name>Sufentanil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sufentanil Bolus</intervention_name>
    <description>Intra-operative sufentanil bolus</description>
    <arm_group_label>Sufentanil Bolus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Scheduled non-emergency cardiac surgical patients including those with planned&#xD;
             procedures of CABG, AVR, and combined CABG and AVR&#xD;
&#xD;
          -  19 to 80 years old&#xD;
&#xD;
          -  Planned pre-operative anesthesia screening visit and/or preoperative surgical clinic&#xD;
             visit.&#xD;
&#xD;
          -  Inpatient subject that is scheduled (greater than 24hrs in advance) for a&#xD;
             non-emergency cardiac surgical case&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Sufentanil allergy&#xD;
&#xD;
          -  EF less than or equal to 30%&#xD;
&#xD;
          -  Moderate or severe right ventricular dysfunction,&#xD;
&#xD;
          -  Moderate pulmonary dysfunction, to include patients with at home 02 and/or daily&#xD;
             bronchodilator therapy.&#xD;
&#xD;
          -  End Stage Renal Disease on Dialysis&#xD;
&#xD;
          -  Chronic Kidney Disease with GFR &lt;30&#xD;
&#xD;
          -  Sternotomy Re-do&#xD;
&#xD;
          -  Emergency surgery&#xD;
&#xD;
          -  Greater than 4 units of RBCs or FFP combined&#xD;
&#xD;
          -  Mechanical circulatory support post-operatively such as ECMO, IABP, Impella&#xD;
&#xD;
          -  Not eligible for rapid wean extubation protocol&#xD;
&#xD;
          -  Requires infusion of sedative medication required during ICU admission&#xD;
&#xD;
          -  Greater than or equal to 15 minute ICU hold within PACU&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jeffrey Songster, MD</last_name>
    <phone>402-559-4455</phone>
    <email>jeffrey.songster@unmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicholas Markin, MD</last_name>
    <phone>402-559-7370</phone>
    <email>nmarkin@unmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Songster, MD</last_name>
      <phone>402-559-7370</phone>
      <email>jeffrey.songster@unmc.edu</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Songster, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>January 9, 2020</study_first_submitted>
  <study_first_submitted_qc>January 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2020</study_first_posted>
  <last_update_submitted>November 3, 2020</last_update_submitted>
  <last_update_submitted_qc>November 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Nebraska</investigator_affiliation>
    <investigator_full_name>Jeffrey Songster MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sufentanil</mesh_term>
    <mesh_term>Dsuvia</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

